Oxiquim S.A (OXIQUIM) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Oxiquim S.A stock CLP 13,273, price CLP 16,400, that is 19.1% below the price, quality 63 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 750.52 CLP – 16,400 CLP · fair‑value band 8,254 CLP – 17,838 CLP · the 16,400 CLP price screens above the 13,273 CLP fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Oxiquim in your weekly email
Every Wednesday you see whether Oxiquim is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oxiquim S.A. engages in the production and sale of resins for the wood board industry in Chile.
Show moreShow less
It offers liquid petroleum gas, clean fuels, wood board, animal feed and nutrition, human food, food flexible packaging films, thermoplastic and compostable resins, paints, coating, and adhesives; industrial water, desalination, purification and treatment; pharmaceuticals and cosmetics, mining, detergents and cleaning, cellulose and paper, HPLC solvents and ACS reagents, and other products.
The company also provides reception, storage, and dispatch services for liquid bulk, serving mining companies, LPG and fuel distributors, pulp mills, paint and coating manufacturers, and resins and adhesive producers.
In addition, it is involved in the distribution and marketing of a range of chemicals, raw materials, and specialties for the productive industry; and marketing, sales and technical support, product development, supply chain and logistics, sourcing and procurement, mixing and formulation, packaging and drumming, and private labeling services.
The company was founded in 1955 and is based in Santiago, Chile.
Stock analysis
Oxiquim S.A (OXIQUIM) currently trades at 16,400 CLP, while our model-based Fair Value estimate is 13,273 CLP, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 16,242 CLP per share, and 2 of the 26 models we run sit above the 16,400 CLP price.
Bear case: the Asset-Based group reads lowest at 3,292 CLP, and 24 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 8,254 CLP (bear) to 17,838 CLP (bull), the price of 16,400 CLP sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Oxiquim S.A reported revenue of 237B CLP in FY2025 versus 191B CLP in FY2021, a compound +5.5%/yr. Reported net income was 26.1B CLP in FY2025, compounding +6.0%/yr from FY2021.
Key figures
Market cap 408B CLP (≈ $418M) Small · P/S ratio 1.78 · EPS (TTM) 1.02 CLP · Dividend yield 3.9% · Net margin 11.0% · Return on equity 21.5% · Return on assets (EBIT) 14.0% (5-year average) · Operating margin 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 45% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −25% fair-value upside, at −19%, OXIQUIM screens cheaper than that median.
Fair Value models
Bear8,254 CLPFair Value 13,273 CLPBull17,838 CLP
Price 16,400 CLP · Downside -19.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Start year 2020 (pandemic). Over 10 years: +5.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’14
’15
’16
’17
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in CLP ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in CLP: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.6%
Dividend (yield on the price)3.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Chile: IMF forecast 3.0% a year to 2030, 4.5% from 2016 to 2025) that is about +11.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 340 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside−19.1% · Below median
Profitability
Return on equity (12 months)21.5% · Top 25%
Return on assets11.6% · Top 25%
Net margin (12 months)11.2% · Above median
Operating margin (12 months)13.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)−2.8% · Bottom 25%
Dividend yield (12 months)3.9% · Top 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
P/B3.34× · Priciest 25%
P/S (12 months)1.81× · Pricier than median
Price / free cash flow (fiscal year)17.8× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oxiquim S.A Fair Value". https://www.fairvalue-calculator.com/stock/OXIQUIM
Frequently asked questions
Is Oxiquim S.A (OXIQUIM) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 13,273 CLP versus a price of 16,400 CLP, about 19% lower (overvalued).
What is the fair value of OXIQUIM?
Our model-based fair value for Oxiquim S.A is 13,273 CLP (as of Nov 8, 2026), built from audited fundamentals. The current price: 16,400 CLP.
What is the quality score of OXIQUIM?
Oxiquim S.A has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oxiquim S.A (OXIQUIM)?
Our model-based price target is the fair value of 13,273 CLP (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 8,254 CLP, optimistic scenario 17,838 CLP. It is a calculation from audited fundamentals, not an analyst target.
What is the Oxiquim S.A stock forecast for 2026?
Our models put fair value at 13,273 CLP, about 19% lower versus a price of 16,400 CLP (overvalued). Cautious scenario 8,254 CLP, optimistic scenario 17,838 CLP. The calculation is refreshed regularly with new filings.
What is the revenue of Oxiquim S.A (OXIQUIM)?
Oxiquim S.A reported trailing-twelve-month revenue of about 226B CLP (latest available figure, as of Nov 8, 2026).
Does Oxiquim S.A pay a dividend?
Oxiquim S.A currently shows a dividend yield of 3.91% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Oxiquim S.A (OXIQUIM) and when is the ex-dividend date?
Oxiquim S.A pays a dividend of 642.00 CLP per share a year, a dividend yield of 3.9%. The last ex-dividend date was Sep 25, 2026. A dividend has been paid every year since 2014. Free cash flow covers the dividend 1.44 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Oxiquim S.A (OXIQUIM)?
For today's price to be fair in a discounted-cash-flow model, Oxiquim S.A would have to grow free cash flow by +15.1 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of OXIQUIM use?
Our models discount Oxiquim S.A at 12.1 %: a base by market capitalisation (small), country premium for Chile. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oxiquim S.A that is +15.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Oxiquim S.A (OXIQUIM) delivered so far?
Over the past 5 years revenue at Oxiquim S.A grew +8.4 % a year. The price currently implies free-cash-flow growth of +15.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oxiquim S.A (OXIQUIM) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into Oxiquim S.A (+15.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oxiquim S.A (OXIQUIM)?
The free-cash-flow yield on the price is 5.62 %: that much free cash flow Oxiquim S.A produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oxiquim S.A (OXIQUIM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oxiquim S.A it is 13,273 CLP per share (as of Nov 8, 2026), against a price of 16,400 CLP. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Oxiquim S.A stock overvalued or undervalued in 2026?
As of Nov 8, 2026, OXIQUIM trades above its calculated fair value: price 16,400 CLP, fair value 13,273 CLP, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OXIQUIM?
No. The price is what the market pays today (16,400 CLP); the fair value is what the company's own numbers justify (13,273 CLP). For Oxiquim S.A the two are 3,127 CLP per share apart. That gap is exactly why we show both numbers side by side.
How much is Oxiquim S.A worth?
The market values Oxiquim S.A at about 408B CLP (market capitalisation, as of Nov 8, 2026). Per share that is 16,400 CLP; our models calculate a fair value of 13,273 CLP per share.
What do the bullish and bearish scenarios say about OXIQUIM?
Our models span a range for Oxiquim S.A: cautious scenario 8,254 CLP, base 13,273 CLP, optimistic 17,838 CLP per share (as of Nov 8, 2026, price 16,400 CLP). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oxiquim S.A (OXIQUIM)?
Balance-sheet figures for Oxiquim S.A (as of Nov 8, 2026): return on equity 21.5%, debt of 0.24 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is OXIQUIM from its 52-week high?
Oxiquim S.A trades at 16,400 CLP, at its 52-week high of 16,400 CLP and 45% above the low of 11,291 CLP (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 13,273 CLP is for.
Which stocks are comparable to Oxiquim S.A?
From the same area (Basic Materials) we also value BASF SE, Saudi Basic Industries Corporation, Dow Inc, Ningxia Baofeng Energy Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oxiquim S.A stock attractive at the current price?
The data as of Nov 8, 2026: price 16,400 CLP, calculated fair value 13,273 CLP (−19%), Quality Score 63/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OXIQUIM calculated?
We run Oxiquim S.A through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 13,273 CLP builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Oxiquim S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oxiquim S.A (OXIQUIM)?
The closing price on Nov 6, 2026 was 16,400 CLP. Our model-based fair value is 13,273 CLP, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oxiquim S.A right now?
Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (8,254 CLP to 17,838 CLP) leaves room in how you read the outcome.
Key figures of Oxiquim S.A
How large is the market capitalisation of Oxiquim S.A (OXIQUIM)?
The market capitalisation of Oxiquim S.A is 408B CLP (≈ $418M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oxiquim S.A (OXIQUIM)?
The price-to-sales ratio of Oxiquim S.A is 1.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oxiquim S.A (OXIQUIM)?
Earnings per share at Oxiquim S.A are 1.02 CLP. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oxiquim S.A (OXIQUIM)?
The dividend yield of Oxiquim S.A is 3.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oxiquim S.A (OXIQUIM)?
The net margin of Oxiquim S.A is 11.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oxiquim S.A (OXIQUIM)?
The return on equity (ROE) of Oxiquim S.A is 21.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oxiquim S.A (OXIQUIM)?
On an EBIT basis the return on assets of Oxiquim S.A is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oxiquim S.A (OXIQUIM)?
The operating margin of Oxiquim S.A is 13.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oxiquim S.A (OXIQUIM)?
Revenue at Oxiquim S.A is growing −2.8% versus a year earlier (3y avg −3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oxiquim S.A (OXIQUIM)?
Earnings per share at Oxiquim S.A are growing +24.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Oxiquim S.A (OXIQUIM) carry?
The net debt of Oxiquim S.A is 47.1B CLP (fiscal year 2025, ≈ 2.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oxiquim S.A in the live analysis
One click puts Oxiquim S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026